Fibroblast growth factor receptors as treatment targets in clinical oncology

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Fibroblast Growth Factor Receptors (FGFRs) are crucial for development and tissue repair.
• Aberrant FGFR signaling, through alterations like amplifications and mutations, contributes to cancer development and progression.
• FGFRs are implicated in various solid tumors, making them therapeutic targets.

Purpose of the Study:

• To review the clinical experience with FGFR inhibitors in cancer treatment.
• To identify key factors for improving response rates and overcoming resistance to FGFR inhibitors.
• To explore strategies for optimizing the use of FGFR inhibitors in clinical practice.

Main Methods:

• Review of clinical trial data and scientific literature on FGFR inhibitors.
• Analysis of patient populations with and without FGFR alterations.
• Evaluation of resistance mechanisms and combination therapy approaches.

Main Results:

• FGFR inhibitors have shown clinical benefits in subsets of patients with solid tumors harboring FGFR alterations.
• Response rates with FGFR inhibitors have been relatively low, with observed responses in patients lacking detectable FGFR alterations.
• Acquired resistance and limited efficacy highlight the need for refined treatment strategies.

Conclusions:

• Improved patient selection is critical to maximize benefit from FGFR inhibitors.
• Combination regimens involving FGFR inhibitors may enhance efficacy and overcome resistance.
• Further research is needed to fully elucidate the potential of FGFR-targeted therapies.